- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about CMPS
Recent news which mentions CMPS
Psychedelic Stock Gainers And Losers From January 21, 2022
January 21, 2022
From Benzinga
Psychedelic Stock Gainers And Losers From January 20, 2022
January 20, 2022
From Benzinga
From Benzinga
Two-Thirds Of Physicians Say Psilocybin Therapy Can Help Treatment-Resistant Depression, New Survey Shows
January 19, 2022
Tickers
CMPS
From Benzinga
Psychedelic Stock Gainers And Losers From January 18, 2022
January 18, 2022
From Benzinga
Psychedelic Stock Gainers And Losers From January 17, 2022
January 17, 2022
From Benzinga
Psyched: Canada's Access To Psychedelic Medicines, Psilocybin No Cognitive Side Effects, Psilocybin Bill Washington
January 10, 2022
From Benzinga
Psilocybin Does Not Produce Adverse Effects On Cognition Or Emotional Function, New Study Finds
January 04, 2022
Tickers
CMPS
From Benzinga
2021 Was The Year Psychedelics Conquered Capitalism...Or Is It The Other Way Around?
December 30, 2021
From Benzinga
Why Jim Cramer Likes MGM Growth Properties
December 21, 2021
From Benzinga
Psychedelics Company COMPASS Pathways To Join NASDAQ Biotechnology Index
December 17, 2021
From Benzinga
Psilocybin Therapy Combined With SSRI Antidepressants Is Possible, COMPASS Study Confirms
December 13, 2021
Tickers
CMPS
From Benzinga
Cannabis Movers & Shakers: Coda Signature, Greater Cannabis Co., BioHarvest Sciences, Compass Pathways
December 06, 2021
From Benzinga
New York City Conference 'Horizons: Perspectives on Psychedelics' A Who's Who Of Notable Speakers
December 03, 2021
Tickers
CMPS
From Benzinga
COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression Reduction
December 01, 2021
Tickers
CMPS
From Benzinga
Peter Thiel-Backed Psychedelic Start-Up, ATAI Life Sciences, Increases Stake In Compass Pathways
November 29, 2021
From Benzinga
Were Compass Pathways' Clinical Trial Results Really That Bad?
November 28, 2021
Tickers
CMPS
From Motley Fool
10 Biggest Price Target Changes For Monday
November 22, 2021
From Benzinga
Better Buy: Compass Pathways vs. Jazz Pharmaceuticals
November 21, 2021
From Motley Fool
How One Company Says It Aims To Demonstrate the Superiority of Psilocin Over Psilocybin in Treating Mental Health Conditions
November 16, 2021
From Benzinga
Is Now the Right Time to Buy Compass Pathways?
November 13, 2021
From Motley Fool
From InvestorPlace
Is Compass Pathways Stock a Once-in-a-Lifetime Bargain?
November 11, 2021
From Motley Fool
75 Biggest Movers From Yesterday
November 10, 2021
From Benzinga
COMPASS Pathways plc (CMPS) Q3 2021 Earnings Call Transcript
November 09, 2021
Tickers
CMPS
From Motley Fool
Why Compass Pathways Shares Are Slumping More Than 22% Tuesday
November 09, 2021
Tickers
CMPS
From Motley Fool
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 09, 2021
From Benzinga
58 Stocks Moving In Monday's Mid-Day Session
November 09, 2021
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.